Holen Sie sich die Stockscreener-App
27.55
1.61%
-0.45
Handel nachbörslich:
27.29
-0.26
-0.94%
Beam Therapeutics Inc Aktie (BEAM) Neueste Nachrichten
Aug Analyst Calls: Will Beam Therapeutics Inc. stock benefit from infrastructure spendingTreasury Yields & Free Community Supported Trade Ideas - ulpravda.ru
Will Beam Therapeutics Inc. stock reach all time highs in 2025Treasury Yields & Proven Capital Preservation Methods - ulpravda.ru
Behavioral Patterns of BEAM and Institutional Flows - Stock Traders Daily
What catalysts could drive Beam Therapeutics Inc. stock higherGap Down & Real-Time Buy Zone Alerts - ulpravda.ru
Will Beam Therapeutics Inc. stock beat EPS estimatesMarket Risk Summary & Weekly Watchlist for Consistent Profits - ulpravda.ru
What dividend safety score for Beam Therapeutics Inc. stock2025 EndofYear Setup & Daily Technical Stock Forecast Reports - ulpravda.ru
How resilient is Beam Therapeutics Inc. stock in market downturnsWatch List & Low Drawdown Momentum Ideas - ulpravda.ru
Gene Editing Tools Market to Reach US$ 1,700.05 million by 2033 | - openPR.com
Bank of America Securities Reaffirms Their Buy Rating on Beam Therapeutics (BEAM) - The Globe and Mail
UBS Initiates Coverage of Beam Therapeutics (BEAM) with Neutral Recommendation - Nasdaq
Is Beam Therapeutics Inc. stock a defensive play in 2025Resistance Zone Identification & Free High Profit Capital Plays - ulpravda.ru
UBS Initiates Coverage on Beam Therapeutics (BEAM) with Neutral - GuruFocus
UBS Initiates Beam Therapeutics at Neutral With $28 Price Target - MarketScreener
Beam upgraded to Buy at BofA Securities on recent genetic condition treatment - MSN
Beam Therapeutics stock initiated with Neutral rating by UBS - Investing.com Australia
How Investors Are Reacting To Beam Therapeutics (BEAM) ARK’s Renewed Bet On Base-Editing Biotech - Yahoo Finance
Beam Therapeutics stock rises 5% after BofA lifts target to $45 - TechStock²
Beam Therapeutics (NASDAQ:BEAM) Shares Up 11.1%What's Next? - MarketBeat
Will Beam Therapeutics Inc. stock benefit from infrastructure spendingStock Price Forecasts & Low Cost Wealth Building - bollywoodhelpline.com
BofA Adjusts Price Target on Beam Therapeutics to $45 From $43, Maintains Buy Rating - MarketScreener
Beam Therapeutics soars 64% after InvestingPro’s undervalued call in April By Investing.com - Investing.com South Africa
ARK Invest Boosts Gene-Editing Bets While Cutting Consumer Tech Exposure - Yahoo Finance
ARK Invest Boosts Stake in Beam Therapeutics (BEAM) Amid Biotech Focus - GuruFocus
Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Rating Increased to Hold at Wall Street Zen - MarketBeat
Beam Therapeutics stock initiated with Neutral rating by UBS By Investing.com - Investing.com Nigeria
Can BEAM's Gene Editing Pipeline Create Long-Term Value Amid Rivalry? - The Globe and Mail
Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks - Sahm
Beam Therapeutics Inc. (BEAM) reports updated data from BEACON Phase 1/2 Trial of Ristoglogene - MSN
Cathie Wood Doubles Down on Biotech as 2025 Ends, Offloads Rocket Lab - TradingView — Track All Markets
Beam Therapeutics Inc. (BEAM) Reports Updated Data From BEACON Phase 1/2 trial Of Ristoglogene - Finviz
Do You Think Beam Therapeutics (BEAM) is an Undervalued Stock? - Yahoo Finance
(BEAM) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
BMO Capital maintains Outperform on Beam Therapeutics stock - MSN
12 Best Genomics Stocks to Invest In - Insider Monkey
Death Cross: Is Beam Therapeutics Inc. stock a defensive play in 2025Exit Point & Safe Entry Zone Identification - moha.gov.vn
Beam Therapeutics (BEAM) Is Up 9.9% After BEACON Data Boosts Confidence In Risto-cel Therapy - simplywall.st
Beam Therapeutics Reaches 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily
BEACON Trial Data Makes Beam Therapeutics (BEAM) an Attractive Buy - Finviz
Prime Editing & CRISPR Market Set to Revolutionize Gene Therapy: - openPR.com
Growth Value: Will Beam Therapeutics Inc. stock benefit from infrastructure spending2025 Price Action Summary & Short-Term High Return Strategies - Улправда
Is Beam Therapeutics Inc. stock a safe investment in uncertain marketsWeekly Trading Summary & Daily Price Action Insights - Улправда
Targets Report: What margin trends mean for Beam Therapeutics Inc. stockPortfolio Performance Report & Expert Approved Trade Ideas - Улправда
Growth Report: Is Beam Therapeutics Inc. stock attractive for retirement portfoliosJuly 2025 Technicals & Reliable Entry Point Alerts - Улправда
Is Beam Therapeutics Inc. stock cheap compared to fundamentalsMarket Growth Report & Short-Term High Return Strategies - Улправда
Price-Driven Insight from (BEAM) for Rule-Based Strategy - Stock Traders Daily
Aug Final Week: Is Beam Therapeutics Inc. stock a defensive play in 2025July 2025 EndofMonth & Free Community Consensus Stock Picks - ulpravda.ru
Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire
What margin trends mean for Beam Therapeutics Inc. stockEarnings Risk Summary & Reliable Volume Spike Alerts - ulpravda.ru
Beam Therapeutics Inc. $BEAM Shares Acquired by Squarepoint Ops LLC - MarketBeat
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):